# Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

> **NCT01203020** · PHASE2 · COMPLETED · sponsor: **West Virginia University** · enrollment: 22 (actual)

## Conditions studied

- Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Busulfan
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT01203020
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10-12
- **Primary completion:** 2021-09-27
- **Final completion:** 2021-09-27
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203020, "Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT01203020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*